<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51655">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433730</url>
  </required_header>
  <id_info>
    <org_study_id>22102014</org_study_id>
    <nct_id>NCT02433730</nct_id>
  </id_info>
  <brief_title>Testosterone Therapy in Hypogonadal Men Treated With Opioids</brief_title>
  <official_title>The Effect of Testosterone Replacement in Patients With Hypogonadotrophic Hypogonadism Due to Opioid Treatment for Non-malignant Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marianne Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of testosterone replacement therapy in
      men with low testosterone due to opioid treatment on body composition, the haemostatic
      system, glucose metabolism, muscle function, pain sensitivity, pain modulation, lipids,
      sexual function and quality of life.

      Male patients on opioids for non-malignant diseases aged 18-59 years diagnosed with
      hypogonadotrophic hypogonadism, referred from day hospitals and outpatient populations. 40
      patients are randomized to either testosterone undecanoate i.m. or placebo i.m., i.e. 20
      patients per arm

      A double blinded randomized placebo controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration is 24 weeks. Patients are treated with Testosterone Undecanoate 1000 mg/4
      ml, intramuscular (i.m.) or placebo at 0, 6 and 18 weeks.

      Outcome measures will be evaluated at 0 and 14 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lean body mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>dual xray absorptiometry scan</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>testosterone</arm_group_label>
    <other_name>nebido</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients 18-59 years

          -  Treatment with opioid for &gt;3 months, daily dose &gt;50-100 mg

          -  Total testosterone &lt; 10 mmol/L

          -  Follicle Stimulating Hormone (FSH)/Luteinizing Hormone (LH) levels normal og below
             normal laboratory values

          -  Normal prolactin levels

        Exclusion Criteria:

          -  Hematocrit&gt; 54% at screening

          -  Prostate Specific Antigen (PSA) &gt; 3 ng/ml

          -  Routine blood sample values above range (thyroid stimulating hormone; ionized
             calcium, hemoglobin, liver- and kidney function tests)

          -  Severe organic and mental disease

          -  Past or present prostate cancer og breastcancer

          -  Past or present liver tumors og acute or chronic liver diseases

          -  Any current diagnosis og cancer

          -  Acute thromboembolic disease

          -  Previous venous thrombotic embolism and cerebrovascular disease

          -  Uncontrolled hypertension

          -  Chronic debilitating disease

          -  Epilepsy or migraine not adequately controlled by therapy

          -  Severe benign prostate hypertrophy with symptom score &gt;19

          -  Sleep apnea

          -  Alcohol or drug abuse

          -  Implantation of sustained action sex hormone in the last 12 months

          -  Use of oral, buccal or transdermal testosterone in the last two weeks

          -  Blood coagulation irregularities presenting af risk of bleeding after intramuscular
             injection

          -  Treatment with glucocorticoids &gt; 5 mg/day or 5 alfa reductase inhibitors

          -  Hypersensitivity to Nebido

          -  Body mass index &gt; 40 kg/m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odensen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Andersen</last_name>
      <phone>65412502</phone>
      <email>msa@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <phone>65412502</phone>
      <email>msa@dadlnet.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 30, 2016</lastchanged_date>
  <firstreceived_date>January 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Marianne Andersen</investigator_full_name>
    <investigator_title>Professor, MD,</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
